Biodegradable Progesterone Microsphere Delivery System for Osteoporosis Therapy

The purpose of this study was to formulate and characterize a controlled-release biodegradable delivery system of progesterone for the treatment or prevention of osteoporosis. Microspheres of progesterone were formulated using copolymers of poly(glycolic acid-co-dl-lactic acid)(PGLA 50/50 and PGLA 15/85) and poly(L-lactic acid)(L-PLA) of similar molecular weight by the emulsion solvent evaporation technique. The effects of process variables, such as volume fraction, polyvinyl alcohol (PVA) concentration, polymer composition, and stir speed during preparation, on the yield, encapsulation efficiency (EEF), particle size distribution, in vitro release profiles of progesterone, and surface morphology of progesterone microspheres were investigated. Increasing the volume fraction from 9% to 22% increased the EEF without significantly increasing the yield; however, the rate of progesterone release from the microspheres decreased. Increasing the PVA concentration from 1% to 5% had no significant influence on the EEF, but the rate of progesterone release from microspheres increased. Polymer composition had no significant effect on the EEF, but had a significant effect on the particle size distribution, surface morphology, and release rate of progesterone from the microspheres. Stir speed did not have a significant influence on the EEF; however, stir speed influenced particle size distribution and the rate of progesterone release from microspheres of the same sieve-size range. The results suggest that controlled release of progesterone is possible by varying the different process variables, and that PGLA 50/50 provided the slowest release of progesterone. This should provide a means of delivering progesterone for months for the treatment or prevention of osteoporosis in postmenopausal women.

[1]  L. Kuller,et al.  Estrogen replacement therapy and mortality among older women. The study of osteoporotic fractures. , 1997, Archives of internal medicine.

[2]  D. Torgerson,et al.  Randomized trial of osteoporosis screening. Use of hormone replacement therapy and quality-of-life results. , 1997, Archives of internal medicine.

[3]  D. Hartmann.  Morbidity of osteoporosis--can estrogen use make a public health impact? , 1997, Current opinion in obstetrics & gynecology.

[4]  J. Balfour,et al.  Estradiol and Dydrogesterone , 1997, Drugs & aging.

[5]  J. Casez,et al.  Prevention of Postmenopausal Bone Loss Using Tibolone or Conventional Peroral or Transdermal Hormone Replacement Therapy with 17β‐Estradiol and Dydrogesterone , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  S. Gonnelli,et al.  The Usefulness of Bone Turnover in Predicting the Response to Transdermal Estrogen Therapy in Postmenopausal Osteoporosis , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  U. Bellati,et al.  [Efficacy of estrogen-progestin replacement therapy after bone marrow transplantation]. , 1996, Minerva ginecologica.

[8]  C. Tsalamandris,et al.  Present and future of osteoporosis therapy. , 1996, Bone.

[9]  D. Sömjen,et al.  Pretreatment with 1,25(OH)2 vitamin D or 24,25(OH)2 vitamin D increases synergistically responsiveness to sex steroids in skeletal-derived cells , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[10]  D. Anderson,et al.  An audit of oestradiol levels and implant frequency in women undergoing subcutaneous implant therapy , 1995, Clinical endocrinology.

[11]  R. Lindsay.  The burden of osteoporosis: cost. , 1995, The American journal of medicine.

[12]  R. Lindsay.  Osteoporosis: A Guide to Diagnosis, Prevention, and Treatment , 1992 .

[13]  M. Whitehead,et al.  Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women , 1990, The Lancet.

[14]  J M Brady,et al.  Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer ratios. , 1977, Journal of biomedical materials research.

[15]  G. Owusu-Ababio,et al.  Preparation and characterization of ofloxacin microspheres for the eradication of bone associated bacterial biofilm. , 1999, Journal of microencapsulation.

[16]  B. de Lignières.  Hormone replacement therapy: clinical benefits and side-effects. , 1996, Maturitas.

[17]  A. Wittich,et al.  Hormone replacement therapy increases trabecular and cortical bone density in osteoporotic women. , 1996, Medicina.

[18]  M. Chorev,et al.  Approach to discovering novel therapeutic agents for osteoporosis based on integrin receptor blockade , 1995, Biopolymers.

[19]  Alfonso R. Gennaro,et al.  Remington:the science and practice of pharmacy , 1995 .

[20]  L. Porterfield,et al.  Estrogen replacement therapy. , 1991, Advancing clinical care : official journal of NOAADN.

[21]  R. Jalil,et al.  Microencapsulation using poly(DL-lactic acid). II: Effect of polymer molecular weight on the microcapsule properties. , 1990, Journal of microencapsulation.

[22]  R. Jalil,et al.  Microencapsulation using poly (L-lactic acid) III: Effect of polymer molecular weight on the microcapsule properties. , 1990, Journal of microencapsulation.

[23]  C. Christiansen,et al.  The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. , 1987, American journal of obstetrics and gynecology.

[24]  J L Kelsey,et al.  Epidemiology of osteoporosis and osteoporotic fractures. , 1985, Epidemiologic reviews.